Relmada Therapeutics (RLMD) Tops Q1 EPS by 3c

Relmada Therapeutics (NASDAQ: RLMD) reported Q1 EPS of ($0.87), $0.03 better than the analyst estimate of ($0.90).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
• Korn Ferry (KFY) Tops Q1 EPS by 7c, Beats on Revenue; Offers Q2 EPS Guidance
• ABM Industries (ABM) PT Raised to $51.50 at UBS, Neutral Rating Maintained